Cargando…

Research progress of Claudin-low breast cancer

Claudin-low breast cancer (CLBC) is a subgroup of breast cancer discovered at the molecular level in 2007. Claudin is one of the primary proteins that make up tight junctions, and it plays crucial roles in anti-inflammatory and antitumor responses as well as the maintenance of water and electrolyte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Chenglong, Xu, Anqi, Ma, Xiaoling, Yao, Yanfei, Zhao, Youmei, Wang, Chunyan, Chen, Ceshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613467/ https://www.ncbi.nlm.nih.gov/pubmed/37904877 http://dx.doi.org/10.3389/fonc.2023.1226118

Ejemplares similares

Extra Spindle Pole Bodies-Like 1 Serves as a Prognostic Biomarker and Promotes Lung Adenocarcinoma Metastasis
por: Nie, Zhi, et al.
Publicado: (2022)

Claudin and pancreatic cancer
por: Wang, Chen, et al.
Publicado: (2023)

Identification of Differentially Expressed Hub Genes Associated With Immune Cell Recruitment in Claudin-Low Breast Cancer
por: Wang, Yange, et al.
Publicado: (2022)

The role and mechanism of claudins in cancer
por: Wang, De-Wen, et al.
Publicado: (2022)

Progress of Breast Cancer basic research in China
por: Wang, Xuerong, et al.
Publicado: (2021)

Research Progress on Circular RNA in Glioma
por: Chen, Mengyu, et al.
Publicado: (2021)

Context-Dependent Roles of Claudins in Tumorigenesis
por: Li, Jian
Publicado: (2021)

Epigenetic Regulation of Claudin-1 in the Development of Ovarian Cancer Recurrence and Drug Resistance
por: Visco, Zachary R., et al.
Publicado: (2021)

Correlation analysis of circulating tumor cells and Claudin-4 in breast cancer
por: Chai, Jie, et al.
Publicado: (2023)

Immune checkpoint inhibitors in cervical cancer: Current status and research progress
por: Xie, Yunkai, et al.
Publicado: (2022)

Claudin-Low Breast Cancer; Clinical & Pathological Characteristics
por: Dias, Kay, et al.
Publicado: (2017)

Differential response to exercise in claudin-low breast cancer
por: Glass, Oliver K., et al.
Publicado: (2017)

Surgical Staging of Locally Advanced Cervical Cancer: Current Status and Research Progress
por: Zhang, He, et al.
Publicado: (2022)

HER3 Differentiates Basal From Claudin Type Triple Negative Breast Cancer and Contributes to Drug and Microenvironmental Induced Resistance
por: Sinevici, Nicoleta, et al.
Publicado: (2020)

Research progress on RNA−binding proteins in breast cancer
por: Chen, Ying, et al.
Publicado: (2022)

The progress in our understanding of CIN in breast cancer research
por: Liao, Yu-Yang, et al.
Publicado: (2023)

EMT Features in Claudin-Low versus Claudin-Non-Suppressed Breast Cancers and the Role of Epigenetic Modifications
por: Voutsadakis, Ioannis A.
Publicado: (2023)

Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients
por: Romani, Chiara, et al.
Publicado: (2020)

Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant Chemotherapy
por: Liu, Yushi, et al.
Publicado: (2022)

Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis
por: Ungureanu, Bogdan Silviu, et al.
Publicado: (2021)

Radiolabeled cCPE Peptides for SPECT Imaging of Claudin-4 Overexpression in Pancreatic Cancer
por: Torres, Julia Baguña, et al.
Publicado: (2020)

Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy
por: Zhang, Wenxiang, et al.
Publicado: (2021)

Re-definition of claudin-low as a breast cancer phenotype
por: Fougner, Christian, et al.
Publicado: (2020)

Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress
por: Chen, Yushi, et al.
Publicado: (2023)

Research Progress of Sirtuin4 in Cancer
por: Bai, Yibing, et al.
Publicado: (2021)

Contribution of the Low-Density Lipoprotein Receptor Family to Breast Cancer Progression
por: Campion, Océane, et al.
Publicado: (2020)

Research progress of cancer cell membrane coated nanoparticles for the diagnosis and therapy of breast cancer
por: Zhou, Zixia, et al.
Publicado: (2023)

Research Progress of Bile Acids in Cancer
por: Fu, Junhao, et al.
Publicado: (2022)

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
por: Prat, Aleix, et al.
Publicado: (2010)

Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization
por: Sabatier, Renaud, et al.
Publicado: (2014)

Prognostic Significance of Low Claudin3 Expression in Luminal Breast Cancers
por: Mudduwa, Lakmini, et al.
Publicado: (2017)

Research Progress on the Role of Regulatory T Cell in Tumor Microenvironment in the Treatment of Breast Cancer
por: Liu, Jianyu, et al.
Publicado: (2021)

Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer
por: Zhang, Hongsheng, et al.
Publicado: (2023)

Research progress of nanovaccine in anti-tumor immunotherapy
por: Yao, Min, et al.
Publicado: (2023)

Claudin 1 in Breast Tumorigenesis: Revelation of a Possible Novel “Claudin High” Subset of Breast Cancers
por: Myal, Yvonne, et al.
Publicado: (2010)

A bibliometric analysis of research progress on pharmacovigilance and cancer from 2002 to 2021
por: Sa, Rina, et al.
Publicado: (2023)

DOCK1 Regulates Growth and Motility through the RRP1B-Claudin-1 Pathway in Claudin-Low Breast Cancer Cells
por: Chiang, Shih-Kai, et al.
Publicado: (2019)

Research Progress of DUB Enzyme in Hepatocellular Carcinoma
por: Zhao, Jie, et al.
Publicado: (2022)

Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer
por: Chang, Jun, et al.
Publicado: (2020)

Research progress of Bub3 gene in malignant tumors
por: Wang, Chenyang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v2osaghfo6busgrl214gj98oh7